CSM
GILD icon

CAMG Solamere Management’s Gilead Sciences GILD Stock Holding History

CAMG Solamere Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-27,707
Closed -$1.99M – 140
2017
Q4 		$1.99M Buy
27,707
+3,211
+13% +$244K 0.88% 44
2017
Q3 		$1.99M Sell
24,496
-4,013
-14% -$307K 0.99% 39
2017
Q2 		$2.02M Buy
28,509
+618
+2% +$41.1K 1.15% 35
2017
Q1 		$1.89M Buy
27,891
+11,604
+71% +$816K 1.11% 36
2016
Q4 		$1.17M Buy
+16,287
New +$1.21M 0.82% 40

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CAMG Solamere Management's GILD Position: Q1 2018 in Review

CAMG Solamere Management sold out of Gilead Sciences (GILD) in Q1 2018, closing a stake of 27,707 shares — an estimated $1.99M sold.

CAMG Solamere Management first reported a position in GILD in Q4 2016 and held it in 5 quarters. The position peaked at $2.02M in Q2 2017. 1,564 funds tracked by Wall St. Rank hold GILD as of Q1 2018.

  • CAMG Solamere Management reported no remaining Gilead Sciences position as of Q1 2018 after selling out during the quarter.
  • CAMG Solamere Management sold 27,707 Gilead Sciences shares in Q1 2018, an estimated $1.99M.
  • CAMG Solamere Management first reported a position in Gilead Sciences in Q4 2016 and held it in 5 quarters.
  • CAMG Solamere Management's Gilead Sciences position peaked at $2.02M in Q2 2017.
  • 1,564 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2018.

Based on CAMG Solamere Management's 13F filing for Q1 2018, filed 15 May 2018.